Adamis Pharmaceuticals Announces a Publication with the Human Immune Monitoring Center at Stanford Demonstrating Tempol Significantly Inhibited Multiple Cytokines from COVID-19 Patient s Cells biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
US pharma gets green light to start human trial for new Covid-19 treatment
A San Diego-based pharmaceutical company has been given the green light to start human trials for a new Covid-19 treatment.
The U.S. Food and Drug Administration (FDA) confirmed today that Adamis Pharmaceutcals may start testing its Tempol drug for the treatment of Covid-19. Earlier studies showed that Tempol reduces inflamation and helps Coronavirus-infected patients early in the infection.
Adamis said in a statement that it plans to examine markers of inflammation and the rate of hospitalization for patients taking Tempol versus placebo early in Covid-19 infection.
Published: Jan 28, 2021
SAN DIEGO, Jan. 28, 2021 (GLOBE NEWSWIRE)
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) in collaboration with the Human Immune Monitoring Center at Stanford University have conducted a study to investigate the effects of Tempol on immune cells from COVID-19 patients. Preliminary data from that study shows that Tempol decreases cytokines from stimulated cells from COVID-19 patients. The collaboration expects to submit the final data to a peer reviewed journal.
Tempol has previously demonstrated both potent anti-inflammatory, anticoagulant, and antioxidant activity. Both inflammatory cytokines and reactive oxygen species (ROS) from cells of the immune system called macrophages and neutrophils damage the lung in Acute Respiratory Distress Syndrome (ARDS). In animal models, Tempol has been shown to decrease proinflammatory cytokines (cytokine storm), and through its potent antioxidant activity has been shown to decrease the harmful ef